AlphaValue recorded Hikma Pharmaceuticals PLC (LON:HIK), retaining its target price at 2,431.00GBX today
- Updated: November 30, 2016
Hikma Pharmaceuticals PLC (LON:HIK) had its target hold steady to 2,431.00GBX by AlphaValue in a report released 11/30/2016. The new target price indicates a possible upside of 0.43% based on the company's previous stock price.
Only yesterday Hikma Pharmaceuticals PLC (LON:HIK) traded 1.71% higher at 1,699.50GBX. Hikma Pharmaceuticals PLC’s 50-day average is 1,792.11GBX and its two hundred day average is 2,167.02GBX. With the last stock price close down -21.67% relative to the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time period. 932,163 shares of the stock were exchanged, up from an avg. volume of 675,576
Recent Performance Chart
Hikma Pharmaceuticals PLC has a 52 week low of 1,575.00GBX and a one year high of 2,703.00GBX with a price-earnings ratio of 20.75 HIK’s total market value is presently 0 GBX.
Also covering Hikma Pharmaceuticals PLC's price target, a total of 9 brokerages have issued a ratings update on the company. The average stock price target is 32.71GBX with four equity analysts rating the company a strong buy, six equity analysts rating the company a buy, zero analysts rating the company a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
Brief Synopsis On Hikma Pharmaceuticals PLC (LON:HIK)
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The Company's segments include Branded, Injectables, Generics and Others. The Branded business sells branded generics and in-licensed products across the MENA region and other markets. The Injectables business sells specialized generic injectable products across the globe. The Generics business sells non-injectable generic products in the United States. The Branded business has approximately 380 products in over 1,120 dosage forms and strengths. Its products include Amoclan, Blopress, Omnicef, Prograf and Suprax. The Injectables business' products include Argatroban, Fentanyl, Glycopyrrolate, Nicardipine and Phenylephrine.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.